Go to the list of all blogs
Dem Sem's Avatar
published in Blogs
Sep 14, 2023
Vascular Tickers $ANGO, $AORT, $LMAT, $AKBA, and $AVGR Surge +252.11% in a Single Day

Vascular Tickers $ANGO, $AORT, $LMAT, $AKBA, and $AVGR Surge +252.11% in a Single Day

 

The Vascular group of tickers has recently made waves by recording a staggering +252.11% increase in performance over just one day. This remarkable surge has garnered significant attention from investors and traders alike, prompting a closer examination of the theme and the individual tickers within it.

Vascular Tickers in Focus: $ANGO$AORT$LMAT$AKBA and $AVGR

The Vascular theme is represented by a group of five tickers: ANGO, AORT, LMAT, AKBA, and AVGR. These companies operate in the vascular industry, which encompasses a wide range of medical and healthcare-related activities. While this theme has recently experienced a surge in performance, it's essential to consider both short-term and long-term factors when evaluating investment opportunities within this sector.

Negative Outlook with Bearish Predictions

Despite the recent surge, Tickeron, a prominent market prediction source, has a negative outlook on this group of vascular tickers. Tickeron predicts a potential decline of more than 4.00% within the next month, with a likelihood of 61%. This bearish forecast suggests that investors should exercise caution and conduct thorough research before considering investments in these stocks.

Volume Trends and Market Sentiment

Analyzing volume trends can provide valuable insights into market sentiment. Over the last month, the daily ratio of advancing to declining volumes in the vascular theme was 1 to 1.18. This indicates that there has been a balance between buying and selling activity within this sector, contributing to the recent price surge.

Market Capitalization Diversity

The market capitalization of companies within the vascular theme varies significantly. On average, these companies have a market capitalization of approximately $490.6 million. Among the five tickers in focus, LMAT holds the highest valuation, with a market capitalization of $1.3 billion. In contrast, AVGR is the lowest valued company in this group, with a market capitalization of only $4.6 million. This wide range of market caps within the theme highlights the diversity of investment opportunities available in the vascular sector.

Price Performance and Notable News

The price performance of vascular-related stocks has been nothing short of spectacular in the short term. On a weekly basis, the average price growth across all stocks in this theme was an astonishing 200.28%, indicating rapid gains. The average monthly and quarterly price growth figures were equally impressive, standing at 140.05% and 107.46%, respectively. However, it's important to note that these figures represent short-term volatility.

Individual Ticker Analysis

Let's take a closer look at three of the key tickers within this theme:

  1. ANGO: The Aroon Indicator for ANGO entered a downward trend on August 18, 2023. This bearish signal, combined with historical patterns, suggests a potential downward move. Traders may consider selling the stock or buying put options. While ANGO has experienced recent challenges, the stock fell by just 1% during the week of 09/05/23 - 09/12/23.

  2. AORT: AORT saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on September 05, 2023. This bearish signal indicates a possible decline ahead. Historical data shows that in 84% of similar instances, the stock moved lower after such a signal. While AORT experienced a recent -1% decline during the week of 09/05/23 - 09/12/23, it's important to monitor its performance closely.

  3. LMAT: LMAT's MACD Histogram turned positive on August 23, 2023, signaling a potential upward trend. Historical data suggests that in 78% of similar instances, the stock continued to rise over the following month. LMAT has enjoyed a +3% uptrend during the week of 09/05/23 - 09/12/23, and its current price is above the highest support line found by A.I.

In summary, the recent surge in performance within the Vascular theme has been exceptional, but it's crucial for investors to approach this sector with caution due to the negative outlook and bearish predictions. While there are opportunities for short-term gains, the long-term stability of these stocks should be carefully considered. As with any investment, thorough research and risk assessment are essential before making decisions in the ever-changing world of financial markets.

Related Ticker: AVGR, AKBA, AORT, ANGO, LMAT

Contributor

Dem Sem's AvatarDem Sem|Expert

View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of catheter devices used to treat vascular diseases

Industry MedicalSpecialties

Profile
Details
Industry
Medical Specialties
Address
400 Chesapeake Drive
Phone
+1 650 241-7900
Employees
72
Web
https://avinger.com
Interact to see
Advertisement
IGV has rallied about 8–9% in the last 6 trading days, while SOXX has dropped about 8%, giving software a +16.6 percentage‑point edge—the largest 6‑day software‑over‑semi outperformance ever.[barchart]​ This comes right after software lagged semis by almost −15 percentage points into late January, the widest gap since 2008, and as hedge‑fund short exposure to U.S. software and services hit a record ~3.8% of market cap.
Crude’s explosive war‑driven spike faded on March 9 because the market suddenly started to price less extreme, shorter‑lived supply risk and more policy intervention, not a multi‑month shortage. WTI, which had briefly traded above 115–120 dollars on Iran‑war headlines and Strait of Hormuz fears, slid back toward the high‑80s as traders digested G7 reserve‑release talk, Trump’s comments about a “brief” war, and the reality that prices had run far ahead of fundamentals.
Shares of ARQ plunged approximately 27.50% in premarket trading on March 10, 2026, from a prior close of $3.20 to roughly $2.32. The primary catalyst was a deeply disappointing Q4 2025 earnings report, which revealed a net loss of $50.0 million for the quarter versus a net loss of $1.3 million in Q4 2024.
RAIL shares fell approximately 15% in premarket trading on March 10, 2026, following a steep after-hours reaction to disappointing Q4 2025 earnings results released after the close on March 9. The primary catalyst was a significant revenue miss: Q4 revenue came in at $125.6 million, well below consensus estimates near $144–$160 million, representing an 8.8% year-over-year decline.
ZVRA shares surged approximately +17.86% on March 10, 2026, driven by a blockbuster Q4 and full-year 2025 earnings report released before the market open. Primary catalyst: Q4 2025 EPS of $0.19 crushed the consensus estimate of $0.05 — a 280% beat — while revenue of $34.1 million exceeded forecasts by 21.57%.
LITE surged +14.73% on Monday, March 9, 2026, closing at $640.69 versus a prior close of $558.44 on March 6. The primary catalyst was the landmark $2 billion strategic investment by NVIDIA announced March 2, with the market continuing to price in its full implications following a brief post-announcement pullback.
Shares of BNTX fell approximately 22% on Tuesday, March 10, 2026, following a dual shock of disappointing full-year guidance and a surprise leadership upheaval. The primary catalyst was BioNTech's Q4 2025 earnings report, which included a 2026 revenue outlook of €2.0–€2.3 billion — well below analyst consensus and signaling continued pressure from declining COVID-19 vaccine demand.
CNC shares fell approximately 10% during Tuesday's session, extending a prolonged selloff in the managed care sector. The primary catalyst is intensifying investor concern over federal Medicaid and ACA funding cuts tied to the "One Big Beautiful Bill Act" (OBBBA), which threatens to shrink the government-sponsored insurance pools that Centene depends on for the majority of its revenue.
Technology recently peaked near 35% of the S&P 500 and has slipped over the last year, while Energy plus Materials remain near historically low combined weight at roughly 6%, which suggests the gap is still unusually wide.
Average daily equity purchases by retail investors on S&P 500 down days in 2026 are at the highest level on record, running about 100% above the peak intensity seen during the 2021 meme‑stock boom.
Over the past two weeks, PLTR has climbed from roughly the high‑130s to the mid‑150s, a gain of about 12–14%, with a series of strong up days between March 2 and March 6.
AVAV shares dropped approximately 10% in premarket trading on March 11, 2026, following a disappointing Q3 fiscal 2026 earnings report released after the prior session's close. Q3 revenue of $408.0 million came in far below analyst consensus of approximately $475–$488 million, representing a massive top-line miss.
KOS shares are down approximately 20% in premarket trading on March 11, 2026, having shed roughly 20.31% across the last two sessions (Tuesday close and premarket Wednesday). The primary catalyst is Kosmos Energy's announcement of a massive $185.25 million public equity offering priced at $1.90 per share — a steep discount to recent trading levels.
NBIS shares surged approximately +10% in premarket trading on March 11, 2026, from a prior close of $96.32. The primary catalyst is the imminent addition of Nebius Group to the Bloomberg 500 (B500) Index, effective prior to the open of trading on Thursday, March 12, 2026.
ORCL shares surged approximately +10.49% in Wednesday's premarket session, trading around $165.07 versus Tuesday's closing price of $149.40. The primary catalyst is Oracle's Q3 FY2026 earnings beat, with adjusted EPS of $1.79 vs. the $1.70 consensus estimate, and revenue of $17.2 billion topping the $16.92 billion forecast.
Shares of AngloGold Ashanti plc (AU) are down approximately 5.00% in early trading on March 11, 2026, falling from a prior close of $108.26 to around $102.85. The primary driver is a renewed pullback in gold prices, which has weighed heavily on gold mining equities across the board.
HMY shares are trading down approximately 13% in early session trading on March 11, 2026, following the release of the company's H1 FY26 interim results. Revenue of R44.4 billion (~US$2.6 billion) missed analyst consensus estimates of R47.56 billion, a significant shortfall that spooked investors.
FICO fell over 9% today, extending a multi‑week downtrend that has already knocked the stock more than 7% lower since its last earnings update. The decline comes despite strong recent financial results, including double‑digit revenue growth, expanding margins, and repeated earnings beats.
RERE fell roughly 10% today, giving back a portion of its strong gains over the past year and month, as traders reacted to fresh earnings and guidance. The company delivered robust Q4 2025 results, with revenue growth near 30% year over year and earnings per share ahead of consensus estimates, underscoring continued operational momentum.
Top hedge funds like Millennium, Citadel, and Bridgewater showed limited direct accumulation of penny stocks in Q4 2025 13F filings, but rotations into biotech, energy, and defense sectors highlight indirect interest in low-priced plays under $5. New entries and increased positions focused on volatile sectors like biotech (e.g., ABCL) and energy (e.g., AMPY), with full exits from overvalued names signaling a hunt for undervalued pennies amid market uncertainty.